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Abstract
Background: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide and accounts
for one third of maternal deaths in low-income and middle-income countries. PPH can be prevented by active
management of the third stage of labor (AMTSL), a series of steps recommended by the World Health Organization to
be performed by skilled birth attendants (SBAs). Task shifting in the AMTSL step of uterotonic drugs administration to
community health workers, traditional birth attendants and self-administration has been investigated as a strategy to
increase access to quality obstetric care considering persistent SBA and facility-based delivery shortages. The aim of this
study is to assess task shifting in the final step of AMTSL and compare uterine tonus assessment by a SBA to self-
assessment.
Methods and Design: The study is an individual-level two-arm non-inferiority randomized controlled trial (RCT).
A total of 800 women will be recruited in Korle Bu Teaching Hospital in Accra, Ghana. Adult women in labor
at term with an expected vaginal delivery who received antenatal instructions for self-assessment of uterine
tonus will be eligible for inclusion. Women with an increased risk for PPH will be excluded. Women will be
randomized to uterine tone assessment by a skilled birth attendant (midwife) or uterine tone self-assessment
(with the safety back-up of a midwife present in case of PPH or uterine atony). Postpartum blood loss will be
measured through weighing of disposable mats. The main study endpoints are PPH (≥500 ml blood loss),
severe PPH (≥1000 ml blood loss), mean blood loss, and routine maternal and neonatal outcomes.
Participants and caregivers will not be blinded given the nature of the intervention.
Discussion: A reduction of PPH-related maternal mortality requires full implementation of AMTSL. Task
shifting of uterine tone assessment may contribute to increased AMTSL implementation in (clinical) settings
where SBAs capacity is constrained.
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Background
Postpartum hemorrhage is the leading cause of maternal
death
Each year, approximately 287,000 women die because
of preventable causes related to pregnancy and child-
birth [1]. Almost all (99 %) of these deaths occur in
low-income and middle-income countries (LMIC),
with the largest burden in sub-Saharan Africa and
South Asia [1].
The most common cause of maternal death is post-
partum hemorrhage (PPH), defined as blood loss
equal to or greater than 500 ml within 24 h after
birth of the infant. PPH occurs in around 10.5 % of
all deliveries and is responsible for more than 130,000
deaths annually [2, 3]. In sub-Saharan Africa, 33.9 %
of maternal deaths are due to PPH [4].
The maternal mortality ratio of Ghana in 2013 was
380 maternal deaths per 100,000 live births [5]. The
leading cause of maternal deaths was obstetric
hemorrhage, with estimates ranging between 27 and
32 % [6–10].
Causes of PPH include uterine atony, uterine rupture,
incisions, lacerations and coagulopathy, with uterine
atony being the most common cause of PPH. Risk fac-
tors for atony include multiparity (five or more deliver-
ies), polyhydramnios, fetal macrosomia, abnormal
placentation, placental abruption, induced or prolonged
labor and retained placental tissue [2, 11].
AMTSL can prevent PPH
Whether a woman dies from PPH depends largely on ac-
cess to timely and competent obstetric care [12]. PPH
mostly occurs during the third and fourth stages of labor
[2, 13], and active management of the third stage of
labor (AMTSL) can prevent its occurrence. AMTSL is
recommended as a series of steps performed by skilled
birth attendants (SBAs) by the World Health
Organization (WHO) and the international professional
organizations of gynecologists and midwives [2, 13, 14].
The steps include the provision of uterotonic drugs
(oxytocin or misoprostol) immediately upon fetal deliv-
ery, controlled cord traction, massage of the fundus of
the uterus immediately after placental delivery in the ab-
sence of uterotonics, and routine assessment of the uter-
ine tonus every 15 min for the first 2 h postpartum.
Task shifting in AMTSL
AMTSL when performed by SBAs is the “gold stand-
ard” for prevention of PPH [2, 15] and can reduce ex-
cessive blood loss by 50–70 % [16]. This provides a
challenge in many LMIC where the majority of
women live in rural areas and deliver at home with-
out SBAs available, often assisted by traditional birth
attendants or family members who are not educated
in obstetric care [17]. Task shifting of AMTSL to
community health workers, traditional birth atten-
dants, or self-administration has been explored as a
strategy to increase access to quality obstetric care in
response to the obstacles [18].
Of all AMTSL interventions, uterotonic drugs are the
most effective in preventing PPH, although the relative
contribution of each of the AMTSL components has not
been well-studied [2, 19]. Oxytocin is the preferred
uterotonic drug. However, as oxytocin is thermo-
unstable, requires refrigeration and should be injected
by SBAs, misoprostol is considered a safe, cheap and
only slightly less effective alternative [20–23]. The WHO
recommends the provision of misoprostol by community
health workers for PPH prevention in rural areas and
homebirths in absence of SBAs [2, 13]. The community
distribution of misoprostol for self-administration by
women is also widely explored as an option, but cur-
rently not recommended [24–26]. Controlled cord trac-
tion is contraindicated without assistance of a SBA [2].
To the best of our knowledge, there is currently no re-
search or recommendation about the relative contribu-
tion of uterine tonus assessment for the prevention of
PPH available, or the effect of task shifting of uterine
tonus assessment [2, 13, 27]. Therefore, the aim of this
non-inferiority randomized controlled trial (RCT) is to
determine whether there is a difference in outcomes fol-
lowing routine uterine tone assessment every 15 min in
the first 2 h postpartum performed by a SBA (midwife)
compared to self-assessment by a patient.
Methods/Design
Study design
This study will be a pragmatic non-inferiority
individual-level two-arm RCT comparing two strat-
egies of AMTSL.
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Participants
The population base for the current study is pregnant
women admitted in labor at Korle Bu Teaching Hospital
(KBTH). KBTH has approximately 10,600 deliveries
every year, approximately 200 per week. AMTSL has
been implemented at KBTH. As a result of midwife un-
derstaffing, the routine assessment of the uterine tone
for the first 2 h postpartum has been delegated to pa-
tients who received adequate training during the ante-
natal care (ANC) visits and who receive a repeated
instruction after delivery. These women are regularly
monitored by midwives. Yet, whether this task shifting is
indeed equally effective has not been formally evaluated.
Inclusion criteria
In order to be eligible to participate in this study, the
following criteria must be met: be at least 18 years of
age, in labor with an expected vaginal delivery of a term
singleton gestation, and recipient antenatal instructions
on postnatal uterine tonus self-assessment.
Exclusion criteria
The following criteria will result in exclusion from study
participation: operative delivery, severe anemia (<8 g/dL)
within 2 weeks of delivery, risk factors for PPH (history
of previous PPH, palpable uterine myoma, antepartum
hemorrhage, anticipated breech delivery), intra uterine
fetal death.
Intervention
Participants will be randomly assigned to one of the two
arms:
1. uterine tonus assessment by patient, every 15 min
for the first 2 h (current standard practice).
2. uterine tonus assessment by a SBA (midwife), every
15 min for the first 2 h (guideline recommended
practice).
Study objectives and hypothesis
Primary objective
To determine whether there is a difference in incidence
of PPH (≥500 ml blood loss) following routine uterine
tone assessment every 15 min in the first 2 h postpartum
performed by a SBA (midwife) compared to self-
assessment by a patient.
Secondary objective
To determine whether routine uterine tonus assessment
every 15 min in the first 2 h postpartum when per-
formed by a SBA (midwife) compared to self-assessed by
a patient, results in differences in incidence of severe
PPH (≥1000 ml blood loss), differences in mean blood
loss, use of additional uterotonics, use of other
procedures for management of PPH (surgery, manual
placenta tissue removal), blood transfusion, maternal re-
suscitation and maternal death.
Other study endpoints and parameters
Neonatal outcomes will be assessed by: Apgar scores at
1 and 5 mins, neonatal resuscitation or perinatal death.
The following socio-demographic and obstetric char-
acteristics will be collected: age, marital status, employ-
ment, education, number of previous pregnancies,
number of previous deliveries (live births and still
births), number of children, present pregnancy history,
medical and surgical history.
Hypothesis
It is hypothesized that there will be no difference in out-
comes for the SBA-assessed group compared to the self-
assessment arm.
Sample size calculation and justification
PPH has an incidence of approximately 11.1 % in the
Ghanaian population [28]. The hypothesis of this non-
inferiority RCT is that there is no difference between the
two treatments. To exclude a difference of between 5 to
7.5 % with a 1-sided alpha co-efficient of 5 % at a power
of 80 %, between 978 and 436 participants would have
to be randomized [29]. Given resource restrictions, our
sample size will be 800 women, and powered to exclude
a difference of 5.53 %.
As the intervention and outcome assessment take
place on the same day, we expect no loss to follow-up.
Study procedures
Recruitment and enrollment
Enrollment will take place at the ANC clinic and on the
antenatal wards of KBTH after informed consent has
been provided. Information about the study will be avail-
able at the ANC clinic and provided during the ANC
education/training for uterine tonus assessment to
familiarize women with the study (see Additional file 1
for the Standardized Operating Procedure for the train-
ing). Patients will be screened for eligibility based on the
previously stated inclusion and exclusion criteria by
trained research assistants. All patients will receive ante-
natal education on uterine tonus self-assessment.
Randomization, treatment allocation, and treatment
concealment
Randomization occurs at presentation at the labor ward
in established labor. If at this stage enrolled patients
present with one of the exclusion criteria, they will be
excluded from the study.
Participants will be assigned a study identification
code based on consecutive enrollment. After the
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identification number has been assigned to a participant,
a matching sealed opaque envelope in which the arm al-
location is concealed can be opened by the research as-
sistant. Women will be assigned an allocation arm while
in labor, but before the onset of birth to facilitate the un-
derstanding of the arm they were allocated – as at time
of full dilation or start of pushing, the ability to absorb
the new information may have been reduced compared
to an earlier stage of labor. The randomization list with
blocks ranging between 2–6 identifiers will begenerated
by the Data Management Department of the University
Medical Center Utrecht using SAS software (SAS Inc.,
Cary, NC, USA). Additional randomization codes can be
created to replace women who were excluded from the
study because of complications, including caesarian
sections.
Because of the nature of the intervention patients, care
providers and research assistants will not be blinded.
Blood loss estimation
Assessment of blood loss will be performed by trained
midwives by weighing blood collected after delivery of
the placenta using disposable mats (“INCO pads”) of 90
x 60 cm. Scales will be standardized and calibrated.
Blood loss will be measured up to 2 h postpartum.
Other outcomes
All other maternal endpoints will be obtained from ma-
ternal record books, surgery record books, antenatal
booklet and interviews.
Disposal of medical waste
Mats used in the study will be disposed according to the
standard procedures of disposal of medical waste at
KBTH.
Standard of care during study participation
Participants will receive the standard of care during their
participation in the study, including all standard care at
KBTH associated with the development, prevention or
treatment of PPH. Women who report inadequate uter-
ine contraction to their midwife, will receive the stand-
ard of care according to PPH protocols of KBTH.
Handling and storage of data and documents
Data will be handled confidentially and anonymously
through assigning a consecutive numeric identification
(ID) code to participants. A separate subject identifica-
tion list will be used to link the participant ID code to
the participant names.
The local investigator(s) have access to the source
data. The key to the code will remain with the coordin-
ating investigator. In accordance to Good Clinical Prac-
tice rules, the dataset will be stored for 15 years.
Statistical analysis
Descriptive statistics for participant characteristics (age,
marital status, employment, education, number of previ-
ous pregnancies, number of previous deliveries (live
births and still births), number of children, present preg-
nancy history, medical and surgical history) will be pre-
sented as frequencies and percentages for dichotomous
and categorical variables, and means and standard devia-
tions for continuous variables will be presented. Differ-
ences between treatment groups will be assessed using
Student’s t test for continuous outcome data and the chi
square test for discrete outcome data, and reported sig-
nificant with a p value of < 0.05.
Analyses for the first and second research objectives
between intervention group and outcomes will be ac-
cording to intention-to-treat. Primary and secondary di-
chotomous, categorical and continuous outcome
variables will be descriptively analyzed in an approach
similar to the participant characteristics analysis.
For the blood loss-related outcomes of interest (PPH,
severe PPH and mean blood loss), linear and logistic re-
gression analysis will be used to analyze the difference
between the two arms. Participant characteristics with
significant differences between the two groups despite
randomization will be considered confounders in a
multivariate logistic or linear regression analysis. The
lower limit of the 90 % confidence interval on the differ-
ence between the groups in frequency of the primary
outcome will be used to assess non-inferiority for these
three variables. Observations with missing outcome data
will not be considered in these analyses.
Ethical considerations
The study will be conducted according to the principles
of the Declaration of Helsinki and in accordance with
the Dutch Law Medical Research Involving Human Sub-
jects Act and Good Clinical Practice. The trial has been
approved by the University of Ghana Medical School
Ethical and Protocol Review Committee (MS-Et/M.8–
P4.1/2014–2015). After information is provided in Twi
or English, participants need to provide written informed
consent (signature or thumb print) before enrollment.
To ensure participant’s rights are protected, an inde-
pendent gynecologist will be available for counseling.
Benefits and risks assessment
There are no direct benefits or incentives for partici-
pants who participate in this study. As the intervention
group receives a midwife assessment of uterine tonus,
the benefit of participating in this study is that PPH may
be detected slightly earlier than may otherwise be the
case. As the study takes places at the labor ward, the
control arm will receive the same quality of care and will
be monitored by the midwives as part of routine care.
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Because most of the data will be collected from collec-
tion books, the time investment is minimized as much
as possible.
All participating women are enrolled in the national
health insurance scheme. No data safety monitoring
board was installed for this study. Details about safety
reporting are available upon request.
Public disclosure and publication policy
This trial has been publicly registered with the Pan-
African Clinical Trials Registry (PACTR,
PACTR201402000736158) and Clinicaltrials.gov
(NCT02223806). Scientific publications will be developed
under the direction of the investigators and disclosed
unreservedly in international scientific peer-reviewed
journals. The full protocol is available upon request.
Discussion
Diagnosis of PPH
Despite the diagnosis of PPH being dependent on the
measurement of blood loss the professional organiza-
tions of gynecologists/obstetricians and midwives [14]
and WHO [2] do not have a recommended standardized
method to measure blood loss. Because visual estimation
has been established to be inaccurate, especially with lar-
ger amounts of blood loss, other more objective
methods to diagnose PPH have been developed. These
methods are direct measurement, gravimetry and pho-
tometry. With direct measurement, blood is directly col-
lected in a pan or collector bag. With photometry, the
amount of blood loss can be determined by a process to
convert blood pigment to alkaline hematine and subse-
quently analyzed. This method is referred to as the “gold
standard.” However, in low resource settings the avail-
ability of this photometric method will be low and the
time needed to extract all blood from linen and pads will
take too long to diagnose PPH. A method commonly
used in clinical practice as an alternative is gravimetry in
which standard-sized pads (e.g. “INCOpads,” 90 x
60 cm) soaked with blood are weighed after delivery of
the placenta, and grams converted to milliliters of blood
loss. Although this method is accurate in diagnosing
PPH, it can overestimate the incidence of PPH, because
it is difficult to discriminate blood from other fluids like
urine or amniotic fluid [30]. In this study, the gravimet-
ric method for diagnosing PPH will be applied.
We acknowledge that this study’s sample size and (clin-
ical) setting may not allow for immediate generalizability
to other settings. Instead, larger studies which include
other clinical settings and non-clinical settings will be ne-
cessary to externally validate the findings before imple-
mentation. Future research could also include the relative
contribution of tonus assessment to the prevention of
PPH, the optimal training program and timing of training.
The experiences of pregnant women and health providers
in task shifting of tonus assessment could also be consid-
ered in future studies.
Trial status
The study will take place from April 2014 until July
2015 at the labor ward of Korle Bu Teaching Hospital in
Accra, Ghana. Enrollment commenced in April 2014.
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